Covington Represents Catalio Capital Management in $38M Strategic Investment in ProSomnus

WASHINGTON– Covington advised Catalio Capital Management LP in its $38 million strategic investment in ProSomnus Sleep Technologies.

Pursuant to the agreement, Catalio has committed up to $38 million to accelerate the development of ProSomnus’ next-generation remote patient monitoring and proprietary sleep diagnostic devices, fund comparative clinical studies, and scale its infrastructure.

Catalio is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public, and credit markets. Catalio has exclusive partnerships with serial scientist-entrepreneurs from around the globe who have started multiple well-established companies based on their research.

ProSomnus provides a technology-enabled, non-CPAP alternative for the treatment of Obstructive Sleep Apnea. It integrates intraoral medical devices with remote patient monitoring and data-driven diagnostics through its sleep health platform.

The Covington team was led by Brent Little, Melanie Cook, and Nancy Marie Rich.